Skip to main content

APEC1621M NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations

NCT04284774

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations

Associated Conditions

Cancer, Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evaluate side effects that might be caused by tipifarnib, which could shrink your cancer but it could cause side effects.